阿司匹林与新型直接口服抗凝药在全髋和全膝关节置换术后静脉血栓栓塞预防中的效果比较:基于英格兰、威尔士、北爱尔兰和马恩岛国家关节登记系统的分析
基于国家关节登记系统218,650例全髋和全膝关节置换患者,倾向性评分匹配后比较阿司匹林与直接凝血酶抑制剂和Xa因子抑制剂的疗效与安全性。全髋置换术后,直接凝血酶抑制剂和Xa因子抑制剂相比阿司匹林与更低的静脉血栓栓塞风险和更短住院时间相关,全膝置换术后结果类似,且未增加短期翻修、再手术、大出血、伤口问题、手术部位感染或死亡风险。
要点
- 全髋置换术后,直接凝血酶抑制剂和Xa因子抑制剂相比阿司匹林与更低的静脉血栓栓塞风险相关。
- 直接口服抗凝药相比阿司匹林与更短的住院时间相关,全膝置换术后结果类似。
- 直接口服抗凝药未增加短期翻修、再手术、大出血、伤口问题、感染或死亡风险。
核心结论
- 全髋和全膝关节置换术后,直接口服抗凝药相比阿司匹林与更低的静脉血栓栓塞风险和更短的住院时间相关,且未增加短期不良事件风险。
研究设计与样本
- 研究基于国家关节登记系统 linked to English hospital inpatient episodes,纳入218,650例全髋和全膝关节置换患者,使用倾向性评分分别将阿司匹林组与直接凝血酶抑制剂组和Xa因子抑制剂组匹配,评估90天结局。
主要发现
- 全膝置换术后静脉血栓栓塞和住院时间的结果与全髋置换术后类似。
- 直接口服抗凝药相比阿司匹林未增加短期翻修手术、再手术、大出血、伤口裂开、手术部位感染和死亡的风险。
临床怎么用
- 在全髋和全膝关节置换术后静脉血栓栓塞预防中,直接口服抗凝药相比阿司匹林可能降低静脉血栓栓塞风险并缩短住院时间,且未增加短期不良事件风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few studies have compared aspirin with direct oral anticoagulants (DOACs) (DOACs = direct thrombin inhibitors and factor Xa inhibitors) for venous thromboembolism (VTE) prophylaxis after total hip arthroplasty (THA) and total knee arthroplasty (TKA). We assessed the efficacy and safety of aspirin compared with DOACs for VTE prophylaxis after THA and TKA using the world's largest joint arthroplasty registry. METHODS: We studied the National Joint Registry linked to English hospital inpatient episodes for 218,650 THA and TKA patients. Patients receiving aspirin were matched separately to patients receiving direct thrombin inhibitors and factor Xa inhibitors using propensity scores. Outcomes assessed at 90 days included VTE, length of stay, and adverse events. RESULTS: After THA, there was a significantly lower risk of VTE associated with the use of direct thrombin inhibitors (0.44%; odds ratio [OR], 0.69; 95% confidence interval [95% CI], 0.55-0.87; P = .002) and factor Xa inhibitors (0.37%; OR, 0.63; 95% CI, 0.47-0.85; P = .003) compared with aspirin (0.63%). After THA, direct thrombin inhibitors (coefficient, -0.37 days; 95% CI, -0.43 to -0.31; P < .001) and factor Xa inhibitors (coefficient, -0.80 days; 95% CI, -0.87 to -0.74; P < .001) were associated with a reduced length of stay compared with aspirin. Similar findings for both outcomes were observed after TKA. Compared with aspirin, DOACs were not associated with an increase in the risk of short-term revision surgery, reoperation, major hemorrhage, wound disruption, surgical site infection, and mortality. CONCLUSION: After THA and TKA, DOACs were associated with a reduced risk of VTE compared with aspirin. DOACs were associated with a reduced length of stay, and DOACs were not associated with an increase in the risk of further surgery, wound problems, bleeding complications, or mortality compared with aspirin.
引用
- Matharu GS, Garriga C, Whitehouse MR, et al. Is Aspirin as Effective as the Newer Direct Oral Anticoagulants for Venous Thromboembolism Prophylaxis After Total Hip and Knee Arthroplasty? An Analysis From the National Joint Registry for England, Wales, Northern Ireland, and the Isle of Man. J Arthroplasty. 2020. PMID: 32532481. doi:10.1016/j.arth.2020.04.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。